Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492249 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R2 | |
| SCHEMBL22678390 | 0.91 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL24713494 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R2 | |
| SCHEMBL4178528 | 0.87 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R2 | |
| SCHEMBL23891075 | 0.87 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL4566190 | 0.86 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R2 | |
| SCHEMBL4174170 | 0.86 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R2 | |
| SCHEMBL24645188 | 0.86 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL4173756 | 0.84 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL27781218 | 0.84 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230248729-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | AMGEN INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248729-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | AMGEN INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011153509-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | PIK3CD 97/4885PIK3CG 146/4885PIK3CB 207/4885 |
| US-20230248729-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | KRAS, NRAS, HRAS | PIK3CD 1032/4885PIK3CG 1052/4885PIK3CB 1431/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CG 54/4885PIK3CB 35/4885 |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | KRAS, NRAS, HRAS | PIK3CD 177/4885PIK3CG 100/4885PIK3CB 277/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | PIK3CD 37/4885PIK3CG 47/4885PIK3CB 73/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | PIK3CD 493/4885PIK3CG 659/4885PIK3CB 504/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | PIK3CD 202/4885PIK3CG 302/4885PIK3CB 276/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | PIK3CD 10/4885PIK3CG 18/4885PIK3CB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.